Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
JAAD Int
.
2021 Jul 1:4:46-48.
doi: 10.1016/j.jdin.2021.05.004.
eCollection 2021 Sep.
Authors
Melinda J Gooderham
1
,
Chia-Yu Chu
2
,
Ricardo Rojo
3
,
Hernan Valdez
4
,
Pinaki Biswas
4
,
Michael C Cameron
4
,
Claire Feeney
5
,
Gerardo A Encinas
6
,
Kathleen Peeples-Lamirande
7
,
Joseph C Cappelleri
3
,
Daniela E Myers
7
,
Marco DiBonaventura
4
Affiliations
1
SKiN Centre for Dermatology, Peterborough, Ontario, Canada.
2
Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
3
Pfizer Inc, Groton, Connecticut.
4
Pfizer Inc, New York, New York.
5
Pfizer Ltd, Surrey, United Kingdom.
6
Pfizer Inc, Vancouver, Canada.
7
Pfizer Inc, Collegeville, Pennsylvania.
PMID:
34409391
PMCID:
PMC8361901
DOI:
10.1016/j.jdin.2021.05.004
No abstract available
Keywords:
abrocitinib; atopic dermatitis; combination therapy; cost; economic impact; monotherapy.